60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · IEX Real-Time Price · USD
0.271
+0.025 (10.16%)
At close: Jul 19, 2024, 4:00 PM
0.240
-0.031 (-11.44%)
Pre-market: Jul 22, 2024, 7:25 AM EDT
Company Description
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States.
The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.
The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
60 Degrees Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jul 12, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Dr. Geoffrey Stuart Dow |
Contact Details
Address: 1025 Connecticut Avenue Nw, Suite 1000 Washington, District of Columbia 20036 United States | |
| Phone | 202-327-5422 |
| Website | 60degreespharma.com |
Stock Details
| Ticker Symbol | SXTP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.30 |
| CIK Code | 0001946563 |
| CUSIP Number | 83006G104 |
| ISIN Number | US83006G1040 |
| Employer ID | 45-2406880 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Geoffrey Stuart Dow | Chairman, Chief Executive Officer and President |
| Tyrone Miller | Chief Financial Officer and Treasurer |
| Dr. Bryan Smith | Chief Medical Officer |
| Kristen Landon | Chief Commercial Officer |
| Jennifer Herz | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 18, 2024 | EFFECT | Notice of Effectiveness |
| Jul 16, 2024 | 8-K | Current Report |
| Jul 12, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 9, 2024 | 8-K | Current Report |
| Jun 27, 2024 | 8-K | Current Report |
| Jun 12, 2024 | 8-K | Current Report |
| May 30, 2024 | DEF 14A | Other definitive proxy statements |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 3, 2024 | PRE 14A | Other preliminary proxy statements |